Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker REG
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Nicholas Andrew Wibbenmeyer Officer | REG Regency Centers Corporation | 7,927 | $624.3K | — | May 5, 2026 | Form 4 ↗ 2 days later · 7,927 shares | Form 144 ↗ |
| May 4, 2026 | Joan Wellhouse Newton 2019 Rev TR Director | REG Regency Centers Corporation | 6,460 | $507.0K | — | May 4, 2026 | Form 4 ↗ 1 day later · 274,615 shares | Form 144 ↗ |
| May 4, 2026 | The Regency Group II, Ltd Director | REG Regency Centers Corporation | 157,892 | $12.4M | — | May 4, 2026 | Form 4 ↗ 1 day later · 274,615 shares | Form 144 ↗ |
| May 4, 2026 | The Regency Group, Inc. Director | REG Regency Centers Corporation | 110,263 | $8.6M | — | May 4, 2026 | Form 4 ↗ 1 day later · 274,615 shares | Form 144 ↗ |
| Mar 11, 2026 | Martin E. Stein Jr. Chairman of the Board | REG Regency Centers Corporation | 38,000 | $2.9M | — | Mar 11, 2026 | Form 4 ↗ same day · 167,490 shares | Form 144 ↗ |
| Mar 10, 2026 | Martin E. Stein Jr. Chairman of the Board | REG Regency Centers Corporation | 129,490 | $10.1M | — | Mar 10, 2026 | Form 4 ↗ 1 day later · 167,490 shares | Form 144 ↗ |
| Feb 20, 2026 | Martin E Stein Jr. Director | REG Regency Centers Corporation | 10,000 | $763.0K | — | Feb 20, 2026 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| Feb 17, 2026 amended | Michael J. Mas Officer | REG Regency Centers Corporation | 15,000 | $1.1M | — | Feb 9, 2026 | — | Form 144/A ↗ |
| Feb 10, 2026 | Roth Alan Todd Officer | REG Regency Centers Corporation | 8,000 | $616.2K | — | Feb 10, 2026 | Form 4 ↗ 1 day later · 8,000 shares | Form 144 ↗ |
| Feb 10, 2026 | Lisa Palmer President | REG Regency Centers Corporation | 26,000 | $2.0M | — | Feb 10, 2026 | Form 4 ↗ same day · 26,000 shares | Form 144 ↗ |
| Nov 12, 2025 | Martin E Stein Jr. Director | REG Regency Centers Corporation | 15,000 | $1.1M | — | Nov 10, 2025 | Form 4 ↗ same day · 15,000 shares | Form 144 ↗ |
| May 21, 2025 | Nicholas Andrew Wibbenmeyer Officer | REG Regency Centers Corporation | 4,158 | $304.1K | — | May 21, 2025 | Form 4 ↗ 2 days later · 4,158 shares | Form 144 ↗ |
| Mar 11, 2025 | The Regency Group, Inc. Chairman of the Board | REG Regency Centers Corporation | 50,000 | $3.7M | — | Mar 11, 2025 | Form 4 ↗ 2 days later · 50,000 shares | Form 144 ↗ |
| Feb 19, 2025 | Lisa Palmer President | REG Regency Centers Corporation | 25,000 | $1.8M | — | Feb 19, 2025 | Form 4 ↗ 1 day later · 25,000 shares | Form 144 ↗ |
| Feb 19, 2025 | Michael J. Mas Officer | REG Regency Centers Corporation | 20,001 | $1.5M | — | Feb 19, 2025 | Form 4 ↗ 1 day later · 20,000 shares | Form 144 ↗ |
| Feb 18, 2025 | Martin Stein Jr Director | REG Regency Centers Corporation | 25,000 | $1.8M | — | Feb 18, 2025 | Form 4 ↗ 2 days later · 25,000 shares | Form 144 ↗ |
| Aug 20, 2024 | Roth Alan Todd Officer | REG Regency Centers Corporation | 4,250 | $299.0K | — | Aug 14, 2024 | — | Form 144 ↗ |
| Aug 20, 2024 | Michael R. Herman Officer | REG Regency Centers Corporation | 1,000 | $69.6K | — | Aug 16, 2024 | — | Form 144 ↗ |
| Aug 13, 2024 amended | Nicholas Andrew Wibbenmeyer Officer, West Region President and Chie… | REG Regency Centers Corporation | 5,549 | $387.8K | — | Aug 9, 2024 | — | Form 144/A ↗ |
| Aug 9, 2024 | Nicholas Andrew Wibbenmeyer Director | REG Regency Centers Corporation | 5,549 | $387.8K | — | Aug 9, 2024 | — | Form 144 ↗ |
| Aug 2, 2024 | Martin E. Stein Jr. Officer, Director | REG Regency Centers Corporation | 25,000 | $1.8M | 10b5-1 | Aug 2, 2024 | — | Form 144 ↗ |
| Feb 21, 2024 | Lisa Palmer Officer | REG Regency Centers Corporation | 25,306 | $1.5M | — | Feb 21, 2024 | — | Form 144 ↗ |
| Dec 14, 2023 | Martin E. Stein Jr. Officer | REG Regency Centers Corporation | 25,000 | $1.7M | 10b5-1 | Dec 14, 2023 | — | Form 144 ↗ |
| Aug 8, 2023 | Nicholas Andrew Wibbenmeyer Officer | REG Regency Centers Corporation | 900 | $59.3K | — | Aug 7, 2023 | — | Form 144 ↗ |
| Aug 7, 2023 | Martin E Stein Jr Director | REG Regency Centers Corporation | 125,000 | $8.3M | — | Aug 7, 2023 | — | Form 144 ↗ |
25 items, most recent first (up to 50). Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:22 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances